Idorsia Pharmaceuticals Ltd.
PharmaAllschwil, Basel-Landschaft, Switzerland · Est. 2017 · 800 employees
Idorsia Pharmaceuticals is a Swiss biopharmaceutical company focused on discovering and developing small molecule drugs for cardiovascular, respiratory, rare disease, and neurological indications.
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
1
Indications↗
Distinct diseases across all programs
100
Clinical Trials↗
All sponsored trials (all statuses)
9
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Phase 31
By Therapeutic Area
top 1
Rare Disease
1100%
R&D Momentum
35/100
Pipeline Velocity
6/100
Trial Completion Rate
93/100
Pipeline Concentration
100/100
Pipeline Freshness
70/100
Activity
Recent Activity
Earlier
Jun 26, 2026TrialA Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo
Jan 18, 2025TrialA Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives
Nov 21, 2024TrialRegistry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
Mar 19, 2024FDATryvio — TRYVIO
Nov 30, 2023TrialDatabase Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)
Jun 23, 2023TrialA Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants
Feb 16, 2023TrialA Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia
4 more events
Jan 16, 2023TrialA Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women
Jan 5, 2023TrialA Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented
Oct 1, 2022TrialA Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects
Sep 6, 2022TrialDose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
Details
Company Info
Company Overview
—
Mkt Cap
$150.0M
Revenue
—
Cash
CEORémi Barbier
Founded2017
Employees800
HQAllschwil, Basel-Landschaft, Switzerland
Websiteidorsia.com
LinkedInCompany Page
Therapeutic Focus
CardiovascularRespiratoryRare diseasesNeurological disorders
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Rare Disease
Rare Disease
Fabry Disease
LucerastatPhase 3
Regulatory
Regulatory Timeline
20221 event
FDAApr 7
Quviviq — QUVIVIQ
Application NDA214985 (NDA)
20241 event
FDAMar 19
Tryvio — TRYVIO
Application NDA217686 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)